Valuation
- Market cap
- 18,777,000
- Revenue TTM
- $1,170,000
- Net income TTM
- $-13,450,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,149.57%
- Debt to equity
- 0.00
Trading
- Volume
- 12,500
- Avg volume
- 46,696
- Day's range
- $3.45 – $3.59
- Shares out
- 5,411,000
- Stochastic %K
- 6%
- Beta
- 0.75
- Analysts
- Hold
- Price target
- $2.30
Company profile
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 pos...
Show more
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 339 240 6066
- Website
- https://www.neuphoriatx.com
- Address
- 14 Milliston Road, Box 195, Millis, United States
Latest news
No headlines yet.
